Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 14/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.78 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.78 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.78 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.78 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.78 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.78 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.78 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16016626 | 0.92 | HDAC1 (0.84) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL31635257 | 0.91 | HDAC4 (0.85) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL6038216 | 0.90 | HDAC1 (0.82) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL16016612 | 0.88 | HDAC1 (0.84) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL675185 | 0.88 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL1063954 | 0.88 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL29921577 | 0.88 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL30029834 | 0.88 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL16016657 | 0.87 | HDAC1 (0.77) | HDAC1HDAC6HDAC3HDAC2HDAC4 | |
| SCHEMBL13363466 | 0.87 | HDAC4 (0.79) | HDAC1HDAC6HDAC3HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374646-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | C & C BIOPHARMA LLC (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150374646-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | C & C BIOPHARMA LLC (US) | 2015-12-31 | — | — | US | disclosed |
| US-20140256776-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | C&C BIOPHARMA, LLC | 2014-09-11 | — | — | US | disclosed |
| US-20140256776-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | C&C BIOPHARMA, LLC | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256776-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | RELA, NCOA1, NCOA2 | HDAC1 163/4885HDAC6 427/4885HDAC3 287/4885 |
| US-20150374646-A1 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR | RELA, NCOA1, NCOA2 | HDAC1 163/4885HDAC6 427/4885HDAC3 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.